Key Highlights

  • AbCellera Biologics (Nasdaq: ABCL) will share Phase 1/2 interim data for ABCL635 at the International Menopause Society World Congress on October 1, 2026.
  • ABCL635 targets moderate-to-severe vasomotor symptoms associated with menopause.
  • Earlier topline data met primary efficacy endpoints, showing statistically significant reductions in frequency and severity after a single dose.
  • Shares of AbCellera Biologics (Nasdaq: ABCL) closed up 3.68% at $12.10.

Interim Data Coming to IMS Congress

AbCellera Biologics (Nasdaq: ABCL) will present Phase 1/2 interim data for ABCL635, its candidate for moderate-to-severe vasomotor symptoms associated with menopause, at the International Menopause Society World Congress on October 1, 2026.

Prior Topline Data Hit Primary Endpoints

The upcoming presentation follows earlier Phase 1/2 topline results in which ABCL635 met its primary efficacy endpoints, achieving statistically significant reductions in both the frequency and severity of vasomotor symptoms at week four compared with placebo, after just a single dose. AbCellera Biologics (Nasdaq: ABCL) has positioned the candidate as a potential option in a therapeutic area with significant unmet need.

Shares Rise Ahead of Congress

Shares of AbCellera Biologics (Nasdaq: ABCL) closed up 3.68% at $12.10, giving the company a market Capitalization of $3.92 billion as investors look ahead to the October data presentation.

What is ABCL635?

An AbCellera Biologics candidate for moderate-to-severe vasomotor symptoms associated with menopause.

What did the topline Phase 1/2 data show?

Statistically significant reductions in frequency and severity of vasomotor symptoms at week four versus placebo after a single dose.

When will interim data be presented?

At the International Menopause Society World Congress on October 1, 2026.